Study:
A Randomized Phase III Trial of ICE Chemotherapy With or Without Rituximab for the Treatment of Relapsed or Refractory CD20 Expressing Aggressive B-Cell Non-Hodgkin`s Lymphomas in Patients Not Suitable for High Dose Therapy and PBSCT
Rationale:
Drugs used in chemotherapy use different ways to stop cancer cells from dividing
so they stop growing or die. Monoclonal antibodies such as rituximab can locate cancer cells
and either kill them or deliver cancer-killing substances to them without harming normal
cells. It is not yet known whether combination chemotherapy is more effective with or
without rituximab for non-Hodgkin`s lymphoma.
Purpose:
Randomized phase III trial to compare the effectiveness of combination chemotherapy
with or without rituximab in treating patients who have relapsed or refractory non-Hodgkin`s
lymphoma.
Study Status: Terminated
Recruiting:
n/a
| Condition |
Intervention |
Phase |
|
Lymphoma |
Biological: filgrastim
Biological: rituximab
Drug: carboplatin
Drug: etoposide
Drug: ifosfamide |
Phase 3 |
Verified by
Southwest Oncology Group
April, 2013
Sponsored by: Southwest Oncology Group
Information provided by: Southwest Oncology Group
ClinicalTrials.gov identifier: NCT00006708
Study Type: Interventional
Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States
David G. Maloney, MD, PhD., Study Chair